## Stephan Ruhrmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5277935/publications.pdf

Version: 2024-02-01

217 papers

14,035 citations

59 h-index 24258 110 g-index

257 all docs

257 docs citations

times ranked

257

11600 citing authors

#	Article	IF	CITATIONS
1	The Psychosis High-Risk State. JAMA Psychiatry, 2013, 70, 107.	11.0	1,222
2	Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell, 2019, 179, 1469-1482.e11.	28.9	935
3	Prediction of Psychosis in Adolescents and Young Adults at High Risk. Archives of General Psychiatry, 2010, 67, 241.	12.3	575
4	Revealing the complex genetic architecture of obsessive–compulsive disorder using meta-analysis. Molecular Psychiatry, 2018, 23, 1181-1188.	7.9	400
5	EPA guidance on the early intervention in clinical high risk states of psychoses. European Psychiatry, 2015, 30, 388-404.	0.2	390
6	EPA guidance on the early detection of clinical high risk states of psychoses. European Psychiatry, 2015, 30, 405-416.	0.2	318
7	Genome-wide association study of obsessive-compulsive disorder. Molecular Psychiatry, 2013, 18, 788-798.	7.9	312
8	Prediction of Psychosis by Mismatch Negativity. Biological Psychiatry, 2011, 69, 959-966.	1.3	273
9	Intervention in Individuals at Ultra-High Risk for Psychosis. Journal of Clinical Psychiatry, 2009, 70, 1206-1212.	2.2	258
10	Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-Onset Depression. JAMA Psychiatry, 2018, 75, 1156.	11.0	251
11	Partitioning the Heritability of Tourette Syndrome and Obsessive Compulsive Disorder Reveals Differences in Genetic Architecture. PLoS Genetics, 2013, 9, e1003864.	3 <b>.</b> 5	241
12	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. Schizophrenia Bulletin, 2014, 40, 729-736.	4.3	229
13	Disorder, not just state of risk: Meta-analysis of functioning and quality of life in people at high risk of psychosis. British Journal of Psychiatry, 2015, 207, 198-206.	2.8	226
14	Sensory Gating in Schizophrenia: P50 and N100 Gating in Antipsychotic-Free Subjects at Risk, First-Episode, and Chronic Patients. Biological Psychiatry, 2008, 64, 376-384.	1.3	212
15	Preventing progression to first-episode psychosis in early initial prodromal states. British Journal of Psychiatry, 2012, 200, 22-29.	2.8	196
16	Application of transcranial magnetic stimulation in treatment of drug-resistant major depression-a report of two cases. Human Psychopharmacology, 1993, 8, 361-365.	1.5	191
17	Basic Symptoms and Ultrahigh Risk Criteria: Symptom Development in the Initial Prodromal State. Schizophrenia Bulletin, 2010, 36, 182-191.	4.3	186
18	Early detection and secondary prevention of psychosis: facts and visions*. European Archives of Psychiatry and Clinical Neuroscience, 2004, 254, 117-128.	3.2	183

#	Article	IF	Citations
19	Neurocognitive indicators for a conversion to psychosis: Comparison of patients in a potentially initial prodromal state who did or did not convert to a psychosis. Schizophrenia Research, 2007, 92, 116-125.	2.0	175
20	Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. British Journal of Psychiatry, 2009, 194, 371-372.	2.8	157
21	Basic Symptoms and the Prediction of First-Episode Psychosis. Current Pharmaceutical Design, 2012, 18, 351-357.	1.9	152
22	Neural correlates of working memory dysfunction in first-episode schizophrenia patients: An fMRI multi-center study. Schizophrenia Research, 2007, 89, 198-210.	2.0	148
23	Impaired mismatch negativity generation in prodromal subjects and patients with schizophrenia. Schizophrenia Research, 2005, 73, 297-310.	2.0	144
24	Probably at-risk, but certainly ill — Advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophrenia Research, 2010, 120, 23-37.	2.0	138
25	Resilience as a multimodal dynamic process. Microbial Biotechnology, 2019, 13, 725-732.	1.7	135
26	Increased neural response related to neutral faces in individuals at risk for psychosis. NeuroImage, 2008, 40, 289-297.	4.2	131
27	Neurocognitive Functioning in Subjects at Risk for a First Episode of Psychosis Compared with First- and Multiple-episode Schizophrenia. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 1388-1407.	1.3	129
28	Gray matter abnormalities in subjects at ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls. Psychiatry Research - Neuroimaging, 2009, 173, 163-169.	1.8	127
29	Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With Clinical High-Risk Syndromes and Recent-Onset Depression. JAMA Psychiatry, 2021, 78, 195.	11.0	125
30	Neuropsychological Profiles in Different At-Risk States of Psychosis: Executive Control Impairment in the Early—and Additional Memory Dysfunction in the Late—Prodromal State. Schizophrenia Bulletin, 2011, 37, 861-873.	4.3	124
31	Early Detection and Intervention in the Initial Prodromal Phase of Schizophrenia. Pharmacopsychiatry, 2003, 36, 162-167.	3.3	122
32	Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry, 2007, 191, s88-s95.	2.8	122
33	Cross-Disorder Genome-Wide Analyses Suggest a Complex Genetic Relationship Between Tourette's Syndrome and OCD. American Journal of Psychiatry, 2015, 172, 82-93.	7.2	117
34	Impulsiveness in obsessive?compulsive disorder: results from a family study. Acta Psychiatrica Scandinavica, 2007, 115, 41-47.	4.5	116
35	Improving the clinical prediction of psychosis by combining ultra-high risk criteria and cognitive basic symptoms. Schizophrenia Research, 2014, 154, 100-106.	2.0	115
36	Disability in people clinically at high risk of psychosis. British Journal of Psychiatry, 2010, 197, 278-284.	2.8	113

#	Article	IF	Citations
37	Copy Number Variation in Obsessive-Compulsive Disorder and Tourette Syndrome: A Cross-Disorder Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 910-919.	0.5	111
38	The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry, 2005, 4, 161-7.	10.4	108
39	Forecasting Psychosis by Event-Related Potentials—Systematic Review and Specific Meta-Analysis. Biological Psychiatry, 2015, 77, 951-958.	1.3	102
40	Prediction and prevention of schizophrenia: what has been achieved and where to go next?. World Psychiatry, 2011, 10, 165-174.	10.4	101
41	Axis I diagnoses and transition to psychosis in clinical high-risk patients EPOS project: Prospective follow-up of 245 clinical high-risk outpatients in four countries. Schizophrenia Research, 2012, 138, 192-197.	2.0	94
42	CSF Metabolic and Proteomic Profiles in Patients Prodromal for Psychosis. PLoS ONE, 2007, 2, e756.	2.5	93
43	Psychosis Prediction: Stratification of Risk Estimation With Information-Processing and Premorbid Functioning Variables. Schizophrenia Bulletin, 2014, 40, 1482-1490.	4.3	91
44	Subjective quality of life in subjects at risk for a first episode of psychosis: A comparison with first episode schizophrenia patients and healthy controls. Schizophrenia Research, 2005, 79, 137-143.	2.0	90
45	Whither the Attenuated Psychosis Syndrome?. Schizophrenia Bulletin, 2012, 38, 1130-1134.	4.3	85
46	Remembering or knowing: electrophysiological evidence for an episodic memory deficit in schizophrenia. Psychological Medicine, 2002, 32, 1261-1271.	4.5	83
47	Familiality of Obsessive-Compulsive Disorder in Nonclinical and Clinical Subjects. American Journal of Psychiatry, 2006, 163, 1986-1992.	7.2	83
48	Auditory P300 in individuals clinically at risk for psychosis. International Journal of Psychophysiology, 2008, 70, 192-205.	1.0	83
49	Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatrica Scandinavica, 2012, 125, 45-53.	4.5	82
50	Binocular depth inversion as a paradigm of reduced visual information processing in prodromal state, antipsychotic-naÃ-ve and treated schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 195-202.	3.2	80
51	Prevalence and Clinical Significance of DSM-5–Attenuated Psychosis Syndrome in Adolescents and Young Adults in the General Population: The Bern Epidemiological At-Risk (BEAR) Study. Schizophrenia Bulletin, 2014, 40, 1499-1508.	4.3	79
52	Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. Psychological Medicine, 1998, 28, 923-933.	4.5	77
53	Basic symptoms in early psychotic and depressive disorders. British Journal of Psychiatry, 2007, 191, s31-s37.	2.8	73
54	Interrelated neuropsychological and anatomical evidence of hippocampal pathology in the at-risk mental state. Psychological Medicine, 2008, 38, 843-851.	4.5	71

#	Article	IF	Citations
55	Dimensions of working memory dysfunction in schizophrenia. Schizophrenia Research, 2003, 62, 259-268.	2.0	70
56	Rationale and First Results of Developing At-Risk (Prodromal) Criteria for Bipolar Disorder. Current Pharmaceutical Design, 2012, 18, 358-375.	1.9	70
57	Reduced subjective quality of life in persons at risk for psychosis. Acta Psychiatrica Scandinavica, 2008, 117, 357-368.	4.5	68
58	The Near Babylonian Speech Confusion in Early Detection of Psychosis. Schizophrenia Bulletin, 2011, 37, 653-655.	4.3	68
59	Self-Reported Psychotic-Like Experiences Are a Poor Estimate of Clinician-Rated Attenuated and Frank Delusions and Hallucinations. Psychopathology, 2014, 47, 194-201.	1.5	65
60	Revisiting the Basic Symptom Concept: Toward Translating Risk Symptoms for Psychosis into Neurobiological Targets. Frontiers in Psychiatry, 2016, 7, 9.	2.6	62
61	Neurophysiological Correlates of Impaired Facial Affect Recognition in Individuals at Risk for Schizophrenia. Schizophrenia Bulletin, 2012, 38, 1021-1029.	4.3	60
62	A Stratified Model for Psychosis Prediction in Clinical Practice. Schizophrenia Bulletin, 2014, 40, 1533-1542.	4.3	59
63	Psychosis-predictive value of self-reported schizotypy in a clinical high-risk sample Journal of Abnormal Psychology, 2016, 125, 923-932.	1.9	59
64	Course of clinical high-risk states for psychosis beyond conversion. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 39-48.	3.2	59
65	Harm avoidance in subjects with obsessive-compulsive disorder and their families. Journal of Affective Disorders, 2008, 107, 265-269.	4.1	58
66	Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry, 2005, 187, s45-s48.	2.8	57
67	Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence. JAMA Psychiatry, 2021, 78, 77.	11.0	57
68	Duration of unspecific prodromal and clinical high risk states, and early help-seeking in first-admission psychosis patients. Social Psychiatry and Psychiatric Epidemiology, 2015, 50, 1831-1841.	3.1	56
69	Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Microbial Biotechnology, 2007, 1, 71-78.	1.7	54
70	A Rose Is a Rose Is a Rose', but At-Risk Criteria Differ. Psychopathology, 2013, 46, 75-87.	1.5	54
71	Pharmacological intervention in the initial prodromal phase of psychosis. European Psychiatry, 2005, 20, 1-6.	0.2	53
72	Integrating evolutionary and regulatory information with a multispecies approach implicates genes and pathways in obsessive-compulsive disorder. Nature Communications, 2017, 8, 774.	12.8	52

#	Article	IF	CITATIONS
73	No Human Tryptophan Hydroxylase-2 Gene R441H Mutation in a Large Cohort of Psychiatric Patients and Control Subjects. Biological Psychiatry, 2006, 60, 202-203.	1.3	49
74	Alexithymia in Obsessive-Compulsive Disorder – Results from a Family Study. Psychotherapy and Psychosomatics, 2006, 75, 312-318.	8.8	48
75	Can quantitative EEG measures predict clinical outcome in subjects at Clinical High Risk for psychosis? A prospective multicenter study. Schizophrenia Research, 2014, 153, 42-47.	2.0	48
76	A promoter variant of SHANK1 affects auditory working memory in schizophrenia patients and in subjects clinically at risk for psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 117-124.	3.2	47
77	Characterization of SLITRK1 Variation in Obsessive-Compulsive Disorder. PLoS ONE, 2013, 8, e70376.	2.5	47
78	Support for the association between the rare functional variant I425V of the serotonin transporter gene and susceptibility to obsessive compulsive disorder. Molecular Psychiatry, 2005, 10, 1059-1061.	7.9	46
79	Kraepelin and psychotic prodromal conditions. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 74-84.	3.2	45
80	Antisaccade performance in patients with obsessive–compulsive disorder and unaffected relatives: further evidence for impaired response inhibition as a candidate endophenotype. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 625-634.	3.2	45
81	Prevalence and clinical relevance of interview-assessed psychosis-risk symptoms in the young adult community. Psychological Medicine, 2018, 48, 1167-1178.	4.5	45
82	Early detection of psychosis – Establishing a service for persons at risk. European Psychiatry, 2009, 24, 1-10.	0.2	43
83	Dysregulated Lipid Metabolism Precedes Onset of Psychosis. Biological Psychiatry, 2021, 89, 288-297.	1.3	42
84	Early onset of obsessive-compulsive disorder and associated comorbidity. Depression and Anxiety, 2009, 26, 1012-1017.	4.1	41
85	Personality disorders and accentuations in atâ€risk persons with and without conversion to firstâ€episode psychosis. Microbial Biotechnology, 2012, 6, 389-398.	1.7	41
86	Prediction of psychosis in clinical high-risk patients by the Schizotypal Personality Questionnaire. Results of the EPOS project. European Psychiatry, 2013, 28, 469-475.	0.2	41
87	Sex differences in the genetic architecture of obsessive–compulsive disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 351-364.	1.7	41
88	Low Plasma Thyroid Indices of Depressed Patients are Attenuated by Antidepressant Drugs and Influence Treatment Outcome. Pharmacopsychiatry, 1996, 29, 180-186.	3.3	40
89	Relationship between subjective and objective cognitive function in the early and late prodrome. British Journal of Psychiatry, 2007, 191, s43-s51.	2.8	40
90	Child Maltreatment and Clinical Outcome in Individuals at Ultra-High Risk for Psychosis in the EU-GEI High Risk Study. Schizophrenia Bulletin, 2018, 44, 584-592.	4.3	38

#	Article	IF	Citations
91	Atypical processing of uncertainty in individuals at risk for psychosis. NeuroImage: Clinical, 2020, 26, 102239.	2.7	37
92	Traces of Trauma: A Multivariate Pattern Analysis of Childhood Trauma, Brain Structure, and Clinical Phenotypes. Biological Psychiatry, 2020, 88, 829-842.	1.3	35
93	The initial prodrome of schizophrenia: different duration, different underlying deficits?. Comprehensive Psychiatry, 2007, 48, 479-488.	3.1	34
94	Obsessive-Compulsive Disorder and Posttraumatic Stress Disorder. Psychopathology, 2008, 41, 129-134.	1.5	34
95	Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia. Schizophrenia Research, 2016, 170, 168-176.	2.0	34
96	DAOA/G72 predicts the progression of prodromal syndromes to first episode psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 209-215.	3.2	33
97	Perceived parental rearing in subjects with obsessive–compulsive disorder and their siblings. Acta Psychiatrica Scandinavica, 2010, 121, 280-288.	4.5	33
98	Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA Cohort. Biological Psychiatry, 2021, 90, 632-642.	1.3	32
99	Psychosocial outcome in patients at clinical high risk of psychosis: a prospective follow-up. Social Psychiatry and Psychiatric Epidemiology, 2013, 48, 303-311.	3.1	31
100	Pathways to care in subjects at high risk for psychotic disorders — A European perspective. Schizophrenia Research, 2014, 152, 400-407.	2.0	31
101	Towards clinical application of prediction models for transition to psychosis: A systematic review and external validation study in the PRONIA sample. Neuroscience and Biobehavioral Reviews, 2021, 125, 478-492.	6.1	31
102	The interaction of working memory and emotion in persons clinically at risk for psychosis: An fMRI pilot study. Schizophrenia Research, 2010, 120, 167-176.	2.0	30
103	Familiality of Obsessive-Compulsive Disorder in Nonclinical and Clinical Subjects. American Journal of Psychiatry, 2006, 163, 1986.	7.2	30
104	Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis. Frontiers in Psychiatry, 2019, 10, 345.	2.6	29
105	Orienting of attention in unmedicated patients with schizophrenia, prodromal subjects and healthy relatives. Schizophrenia Research, 2007, 97, 35-42.	2.0	28
106	Short-term functional outcome and premorbid adjustment in clinical high-risk patients. Results of the EPOS project. European Psychiatry, 2014, 29, 371-380.	0.2	28
107	General psychopathology links burden of recent life events and psychotic symptoms in a network approach. NPJ Schizophrenia, 2020, 6, 40.	3.6	28
108	The interrelationship between schizotypy, clinical high risk for psychosis and related symptoms: Cognitive disturbances matter. Schizophrenia Research, 2019, 210, 188-196.	2.0	27

#	Article	IF	Citations
109	Morphometry of structural disconnectivity indicators in subjects at risk and in age-matched patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 15-24.	3.2	26
110	Restricted attention to social cues in schizophrenia patients. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 649-661.	3.2	26
111	Recurrent brief depression and its relationship to seasonal affective disorder. European Archives of Psychiatry and Clinical Neuroscience, 1992, 242, 20-26.	3.2	25
112	Intervention in the at-risk state to prevent transition to psychosis. Current Opinion in Psychiatry, 2009, 22, 177-183.	6.3	24
113	Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1012-1022.	4.8	23
114	The Strauss and Carpenter Prognostic Scale in subjects clinically at high risk of psychosis. Acta Psychiatrica Scandinavica, 2013, 127, 53-61.	4.5	23
115	5-HT3 receptor influences the washing phenotype and visual organization in obsessive-compulsive disorder supporting 5-HT3 receptor antagonists as novel treatment option. European Neuropsychopharmacology, 2014, 24, 86-94.	0.7	23
116	Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis. JAMA Psychiatry, 2020, 77, 190.	11.0	23
117	Genome-wide association study of pediatric obsessive-compulsive traits: shared genetic risk between traits and disorder. Translational Psychiatry, 2021, 11, 91.	4.8	23
118	Heterogeneity and Classification of Recent Onset Psychosis and Depression: A Multimodal Machine Learning Approach. Schizophrenia Bulletin, 2021, 47, 1130-1140.	4.3	23
119	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Molecular Psychiatry, 2021, 26, 4529-4543.	7.9	23
120	Prediction and prevention of psychosis: current progress and future tasks. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 9-16.	3.2	21
121	Pharmacological Prevention and Treatment in Clinical At-Risk States for Psychosis. Current Pharmaceutical Design, 2012, 18, 550-557.	1.9	20
122	Depression predicts persistence of paranoia in clinical high-risk patients to psychosis: results of the EPOS project. Social Psychiatry and Psychiatric Epidemiology, 2016, 51, 247-257.	3.1	20
123	Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning – Results from the EU-GEI study. European Psychiatry, 2019, 59, 52-59.	0.2	19
124	Age effects on basic symptoms in the community: A route to gain new insight into the neurodevelopment of psychosis?. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 311-324.	3.2	19
125	A Controlled Study of the Efficacy and Safety of Mianserin and Amitriptyline in Depressive Inpatients. Pharmacopsychiatry, 1995, 28, 249-252.	3.3	18
126	Chances and risks of predicting psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 85-90.	3.2	18

#	Article	IF	CITATIONS
127	Antisaccade and prosaccade eye movements in individuals clinically at risk for psychosis: comparison with first-episode schizophrenia and prediction of conversion. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 921-930.	3.2	18
128	Intervention in at-risk states for developing psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 90-94.	3.2	17
129	Expressed emotion as a predictor of the first psychotic episode — Results of the European prediction of psychosis study. Schizophrenia Research, 2018, 199, 346-352.	2.0	17
130	Comparing the prodrome of schizophrenia-spectrum psychoses and affective disorders with and without psychotic features. Schizophrenia Research, 2012, 138, 218-222.	2.0	16
131	Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis. Molecular Psychiatry, 2021, 26, 2590-2604.	7.9	16
132	Antisaccade performance is related to genetic loading for schizophrenia. Journal of Psychiatric Research, 2009, 43, 291-297.	3.1	15
133	Peculiarities of health literacy in people with mental disorders: A cross-sectional study. International Journal of Social Psychiatry, 2020, 66, 10-22.	3.1	15
134	Cognitive subtypes in recent onset psychosis: distinct neurobiological fingerprints?. Neuropsychopharmacology, 2021, 46, 1475-1483.	5.4	15
135	Neurobiologically Based Stratification of Recent-Onset Depression and Psychosis: Identification of Two Distinct Transdiagnostic Phenotypes. Biological Psychiatry, 2022, 92, 552-562.	1.3	15
136	Search for copy number variants in chromosomes 15q11-q13 and 22q11.2 in obsessive compulsive disorder. BMC Medical Genetics, 2010, 11, 100.	2.1	14
137	Childhood adversity predicts persistence of suicidal thoughts differently in females and males at clinical highâ&isk patients of psychosis. Results of the EPOS project. Microbial Biotechnology, 2019, 13, 935-942.	1.7	14
138	Multimodal prevention of first psychotic episode through Nâ€acetylâ€ <scp>l</scp> â€cysteine and integrated preventive psychological intervention in individuals clinically at high risk for psychosis:  Protocol of a randomized, placeboâ€controlled, parallelâ€group trial. Microbial Biotechnology, 2019, 13, 1404-1415.	1.7	14
139	Sex differences in cognitive functioning of patients at-risk for psychosis and healthy controls: Results from the European Gene–Environment Interactions study. European Psychiatry, 2020, 63, e25.	0.2	14
140	Emotion Recognition and Adverse Childhood Experiences in Individuals at Clinical High Risk of Psychosis. Schizophrenia Bulletin, 2020, 46, 823-833.	4.3	14
141	Association between age of cannabis initiation and gray matter covariance networks in recent onset psychosis. Neuropsychopharmacology, 2021, 46, 1484-1493.	5.4	14
142	The German Research Network on Schizophrenia-impact on the management of schizophrenia. Dialogues in Clinical Neuroscience, 2006, 8, 115-121.	3.7	14
143	Perceived negative attitude of others as an early sign of psychosis. European Psychiatry, 2009, 24, 233-238.	0.2	13
144	The Psychopathology and Neuroanatomical Markers of Depression in Early Psychosis. Schizophrenia Bulletin, 2021, 47, 249-258.	4.3	13

#	Article	IF	Citations
145	Neurocognitive functioning in parents of schizophrenia patients: Attentional and executive performance vary with genetic loading. Psychiatry Research, 2015, 230, 885-891.	3.3	12
146	Development of a stage-dependent prognostic model to predict psychosis in ultra-high-risk patients seeking treatment for co-morbid psychiatric disorders. Psychological Medicine, 2016, 46, 1839-1851.	4.5	12
147	Perceived negative attitude of others predicts transition to psychosis in patients at risk of psychosis. European Psychiatry, 2012, 27, 264-266.	0.2	11
148	Relationship between jumping to conclusions and clinical outcomes in people at clinical high-risk for psychosis. Psychological Medicine, 2022, 52, 1569-1577.	4.5	11
149	Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective. Schizophrenia Bulletin, 2021, 47, 1018-1028.	4.3	10
150	The clinical relevance of formal thought disorder in the early stages of psychosis: results from the PRONIA study. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 403-413.	3.2	10
151	Verbal memory performance predicts remission and functional outcome in people at clinical high-risk for psychosis. Schizophrenia Research: Cognition, 2022, 28, 100222.	1.3	10
152	Clinical Response to Sleep Deprivation and Auditory-Evoked Potentials - Preliminary Results. Pharmacopsychiatry, 1994, 27, 70-71.	3.3	9
153	Sex differences in symptomatology of psychosis-risk patients and in prediction of psychosis. Archives of Women's Mental Health, 2020, 23, 339-349.	2.6	9
154	Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis. Schizophrenia Bulletin, 2022, 48, 100-110.	4.3	9
155	Evidence for a seasonal form of recurrent brief depression (RBD-seasonal). European Archives of Psychiatry and Clinical Neuroscience, 1994, 244, 205-210.	3.2	8
156	Personality dimensions in persons symptomatically at risk of psychosis: pronounced but lacking a characteristic profile. Microbial Biotechnology, 2015, 9, 242-247.	1.7	8
157	Validation of the Bullying Scale for Adults - Results of the PRONIA-study. Journal of Psychiatric Research, 2020, 129, 88-97.	3.1	8
158	The functional coding variant Asn107lle of the neuropeptide S receptor gene (NPSR1) influences age at onset of obsessive–compulsive disorder. International Journal of Neuropsychopharmacology, 2013, 16, 1951-1958.	2.1	7
159	Basic Disturbances of Information Processing in Psychosis Prediction. Frontiers in Psychiatry, 2013, 4, 93.	2.6	7
160	Multimodal prognosis of negative symptom severity in individuals at increased risk of developing psychosis. Translational Psychiatry, 2021, 11, 312.	4.8	7
161	A randomized Phase <scp>II</scp> trial evaluating efficacy, safety, and tolerability of oral <scp>BI</scp> 409306 in attenuated psychosis syndrome: Design and rationale. Microbial Biotechnology, 2021, 15, 1315-1325.	1.7	7
162	Pre-training inter-rater reliability of clinical instruments in an international psychosis research project. Schizophrenia Research, 2020, 230, 104-107.	2.0	6

#	Article	IF	Citations
163	The non-specific nature of mental health and structural brain outcomes following childhood trauma. Psychological Medicine, 2023, 53, 1005-1014.	4.5	6
164	Association between tobacco use and symptomatology in individuals at ultra-high risk to develop a psychosis: A longitudinal study. Schizophrenia Research, 2021, 236, 48-53.	2.0	6
165	Clinical, Brain, and Multilevel Clustering in Early Psychosis and Affective Stages. JAMA Psychiatry, 2022, 79, 677.	11.0	6
166	Health literacy in clinicalâ€highâ€risk individuals for psychosis: A systematic mixedâ€methods review. Microbial Biotechnology, 2019, 13, 1293-1309.	1.7	5
167	Basic Symptoms Are Associated With Age in Patients With a Clinical High-Risk State for Psychosis: Results From the PRONIA Study. Frontiers in Psychiatry, 2020, 11, 552175.	2.6	5
168	Physical illnesses, developmental risk factors and psychiatric diagnoses among subjects at risk of psychosis. European Psychiatry, 2013, 28, 135-140.	0.2	3
169	Attitudes towards Risk Prediction in a Help Seeking Population of Early Detection Centers for Mental Disorders—A Qualitative Approach. International Journal of Environmental Research and Public Health, 2021, 18, 1036.	2.6	3
170	Prediction and Early Detection of First-Episode Psychosis., 2011,, 207-267.		3
171	Relationships between global functioning and neuropsychological predictors in subjects at high risk of psychosis or with a recent onset of depression. World Journal of Biological Psychiatry, 2022, 23, 573-581.	2.6	3
172	THE ROLE OF PERSONALITY DISORDER AND ACCENTUATION IN THE CONVERSION TO PSYCHOSIS. Schizophrenia Research, 2010, 117, 422-423.	2.0	2
173	868. Early Intervention in Attenuated Psychosis Syndrome: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306. Biological Psychiatry, 2017, 81, S351.	1.3	2
174	Novel Gyrification Networks Reveal Links with Psychiatric Risk Factors in Early Illness. Cerebral Cortex, 2021, , .	2.9	2
175	Impact of Smoking Behavior on Cognitive Functioning in Persons at Risk for Psychosis and Healthy Controls: A Longitudinal Study. European Psychiatry, 2021, 64, 1-20.	0.2	2
176	MISMATCH NEGATIVITY IS REDUCED IN SCHIZOPHRENIA PATIENTS WITH DEFICIT SYNDROME. Schizophrenia Research, 2010, 117, 360-361.	2.0	1
177	PREVENTIVE PSYCHOTHERAPY. Schizophrenia Research, 2014, 153, S42-S43.	2.0	1
178	Clinical High Risk Symptoms and Criteria in the Community: Prevalence, Clinical Significance and Risk Factors for Their Occurrence. European Psychiatry, 2017, 41, S226-S226.	0.2	1
179	Basic Symptoms in the Community and their Association with Age. European Psychiatry, 2017, 41, S84-S85.	0.2	1
180	Is there a diagnosis-specific influence of childhood trauma on later educational attainment? A machine learning analysis in a large help-seeking sample. Journal of Psychiatric Research, 2021, 138, 591-597.	3.1	1

#	Article	IF	CITATIONS
181	Using combined environmental–clinical classification models to predict role functioning outcome in clinical high-risk states for psychosis and recent-onset depression. British Journal of Psychiatry, 2022, 220, 229-245.	2.8	1
182	Pattern of predictive features of continued cannabis use in patients with recent-onset psychosis and clinical high-risk for psychosis. NPJ Schizophrenia, 2022, 8, 19.	3.6	1
183	381. Sensory gating: new vistas. Biological Psychiatry, 2000, 47, S116.	1.3	0
184	555. Early ERPS and their contribution to diagnosis in schizophrenia. Biological Psychiatry, 2000, 47, S169.	1.3	0
185	EPOS — General outlines of the "European prediction of psychosis study― Schizophrenia Research, 2003, 60, 5.	2.0	0
186	0127 LOCUS OF CONTROL IN PERSONS CLINICALLY AT RISK FOR PSYCHOSIS. Schizophrenia Research, 2006, 86, S85.	2.0	0
187	0372 THE INTERACTION OF NEGATIVE EMOTION AND WORKING MEMORY IN EARLY PSYCHOSIS. Schizophrenia Research, 2006, 86, S109.	2.0	0
188	EPOS - sample characteristics, transition rates and psychopathological predictors. European Psychiatry, 2007, 22, S64.	0.2	0
189	PHARMACOLOGICAL INTERVENTION IN THE PRODROMAL STATE OF PSYCHOSIS. Schizophrenia Research, 2008, 102, 47-48.	2.0	0
190	P.3.f.001 Does anandamide elevation in cerebrospinal fluid protect against transition into frank psychosis?. European Neuropsychopharmacology, 2008, 18, S474.	0.7	0
191	Specific neurocognitive deficits are related to inferred genetic risk in unaffected parents of schizophrenic patients. European Psychiatry, 2008, 23, S28.	0.2	0
192	Subjective quality of life and its changes in patients at risk of psychosis. European Psychiatry, 2008, 23, S68.	0.2	0
193	Transition to psychosis: Neuropsychological test results of the epos study. European Psychiatry, 2008, 23, S68-S69.	0.2	0
194	Antisaccade deficits in subjects either genetically or clinically at risk for schizophrenia. European Psychiatry, 2008, 23, S69.	0.2	0
195	The EPOS prediction model improves ability to predict transition to first episode psychosis in individuals at high risk. Evidence-Based Mental Health, 2010, 13, 77-77.	4.5	0
196	P03-118 - Perceived Negative Attitude Associates with Psychotic Experiences. European Psychiatry, 2010, 25, .	0.2	0
197	PREDICTION OF PSYCHOSIS BY MISMATCH NEGATIVITY. Schizophrenia Research, 2010, 117, 244.	2.0	0
198	BASIC SYMPTOM AND ULTRA-HIGH RISK CRITERIA IN THE PREDICTION OF FIRST-EPISODE PSYCHOSIS. Schizophrenia Research, 2010, 117, 422.	2.0	0

#	Article	IF	CITATIONS
199	Subjective quality of life and its changes in patients at-risk for psychosis results of the EPOS study. European Psychiatry, 2011, 26, 2039-2039.	0.2	О
200	Course of psychopathology in the at-risk mental state - outcomes beyond transition to psychosis. European Psychiatry, 2011, 26, 2037-2037.	0.2	0
201	Poster #202 COMPARING THE PRODROME OF SCHIZOPHRENIA-SPECTRUM PSYCHOSES AND BIPOLAR DISORDERS WITH AND WITHOUT PSYCHOTIC FEATURES. Schizophrenia Research, 2012, 136, S163-S164.	2.0	0
202	Poster #70 COPING IN INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS, SCHIZOPHRENIA PATIENTS AND HEALTHY CONTROL SUBJECTS. Schizophrenia Research, 2012, 136, S210-S211.	2.0	0
203	Poster #191 THE STRAUSS AND CARPENTER PROGNOSTIC SCALE IN SUBJECTS CLINICALLY AT HIGH RISK OF PSYCHOSIS. Schizophrenia Research, 2012, 136, S254.	2.0	O
204	Causal Connection Between Depression and Paranoia. European Psychiatry, 2015, 30, 113.	0.2	0
205	TTe Predictive Power of the Wisconsin Scales of Schizophrenia Proneness in Patients of an Early Detection Service. European Psychiatry, 2015, 30, 922.	0.2	O
206	Authors' reply. British Journal of Psychiatry, 2016, 208, 197-198.	2.8	0
207	Electroencephalographic Predictors of Psychosis. Key Issues in Mental Health, 0, , 133-141.	0.6	O
208	Intervention in Clinical High Risk States - Current Status and Future Perspectives. European Psychiatry, 2017, 41, S27-S28.	0.2	0
209	T239. SINGLE-SUBJECT PREDICTION OF FUNCTIONAL OUTCOMES IN CLINICAL HIGH RISK SUBJECTS USING CLINICAL DATA. Schizophrenia Bulletin, 2018, 44, S209-S210.	4.3	O
210	S13. DO PATIENTS WITH RECENT-ONSET DEPRESSION DIFFER CLINICALLY AND NEUROBIOLOGICALLY FROM DEPRESSED PATIENTS WITH A CLINICAL HIGH-RISK STATE FOR PSYCHOSIS?. Schizophrenia Bulletin, 2018, 44, S328-S329.	4.3	0
211	O6.5. INVESTIGATING VARIABLES FROM THE NAPLS RISK CALCULATOR FOR PSYCHOSIS IN THE EU-GEI HIGH RISK STUDY. Schizophrenia Bulletin, 2019, 45, S177-S178.	4.3	О
212	S94. PREDICTION OF CANNABIS RELAPSE IN CLINICAL HIGH-RISK INDIVIDUALS AND RECENT ONSET PSYCHOSIS - PRELIMINARY RESULTS FROM THE PRONIA STUDY. Schizophrenia Bulletin, 2020, 46, S69-S70.	4.3	0
213	Detailed clinical phenotyping and generalisability in prognostic models of functioning in at-risk populations. British Journal of Psychiatry, 2021, , 1-4.	2.8	O
214	A longitudinal multi-center fMRI study of cognition and emotion in first-episode schizophrenia patients. Pharmacopsychiatry, 2003, 36, .	3.3	0
215	Intervenci $ ilde{A}^3$ n farmacol $ ilde{A}^3$ gica en la fase prodr $ ilde{A}^3$ mica inicial de la psicosis. European Psychiatry (Ed) Tj ETQq $1\ 1\ 0.7$	784314 rg 0.0	BT /Overloc
216	Prevention and Early Intervention in At-Risk States for Developing Psychosis., 2011,, 81-92.		0

#	Article	IF	CITATIONS
217	Impact of smoking behavior on cognitive functioning in persons at risk for psychosis and healthy controls: A longitudinal study – CORRIGENDUM. European Psychiatry, 2022, 65, e17.	0.2	0